Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria
Year: 2016
Type: article
Abstract: RATIONALE: In the absence of a surgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS trials of nintedanib if they had honeycombing and/or traction bronchiectasis plus reticulation, without atypical features of usual interstitial pneumonia (UIP), on high-resolution computed tomography (HRCT). Thus, the patients in these trials represented patients with definite UIP and a large subgroup of patients with possible UIP. OBJECTIVES: To investigate the potential impact of diagnostic subgroups on the progression of IPF and the effect of nintedanib. METHODS: We conducted a post hoc subgroup analysis of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy versus patients without either, using pooled data from the INPULSIS trials. MEASUREMENTS AND MAIN RESULTS: Seven hundred twenty-three (68.1%) patients had honeycombing and/or biopsy, and 338 (31.9%) patients had no honeycombing or biopsy. In these subgroups, respectively, the adjusted annual rate of decline in FVC in patients treated with placebo was -225.7 and -221.0 ml/yr, and the nintedanib versus placebo difference in the adjusted annual rate of decline in FVC was 117.0 ml/yr (95% confidence interval, 76.3-157.8) and 98.9 ml/yr (95% confidence interval, 36.4-161.5). There was no significant treatment-by-subgroup interaction (P = 0.8139). Adverse events were similar between the subgroups. CONCLUSIONS: Patients with IPF diagnosed in clinical practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lung biopsy had disease that progressed in a similar way, and responded similarly to nintedanib, to that of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy.
Authors: Ganesh Raghu, Athol U. Wells, Andrew G. Nicholson, Luca Richeldi, Kevin R. Flaherty, Florence Le Maulf, Susanne Stowasser, Rozsa Schlenker-Herceg, David M. Hansell
Institutions: University of Washington, Royal Brompton & Harefield NHS Foundation Trust, Imperial College London, National Institute for Health and Care Research, NIHR Southampton Respiratory Biomedical Research Unit, University of Southampton, Michigan Medicine, Boehringer Ingelheim (France), Boehringer Ingelheim (Germany), Boehringer Ingelheim (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2474839550
